Health: Artificial heartmaker Carmat to start sales after EU approval gdnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gdnonline.com Daily Mail and Mail on Sunday newspapers.
SHARE
Shares in Carmat posted their biggest gain in more than seven years after the company got approval to sell the first-ever total artificial heart in Europe, the culmination of a 27-year effort that began with a pitch from a French cardiac surgeon to an aerospace company.
The stock climbed 34 per cent to €32.05 ($39.04) at 11.29am in Paris on Friday after rising as much as 50 per cent, its steepest intraday gain since May 2013. Carmat shares have advanced 66 per cent this year, giving the company a market value of about €407 million ($496m).
Carmat this week obtained a CE mark for the device, meaning the company can now sell it in the European Union as a bridge to a heart transplant for patients suffering from irreversible end-stage heart failure.